 |
 |
|
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Blood Thinner Use in Patients with Atrial Fibrillation
21 December 1999 | Volume 131 Issue 12 | Page 927
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study." It is in the 12 December 1999 issue of Annals of Internal Medicine (volume 131, pages 927-934). The authors are A.S. Go, E.M. Hylek, L.H. Borowsky, K.A. Phillips, J.V. Selby, and D.E. Singer.
What is the problem and what is known about it so far?
Atrial fibrillation is a kind of irregular heart rhythm. People with atrial fibrillation sometimes develop blood clots in their hearts. This may lead to stroke if pieces of the clot break off and travel from the heart to the brain. Warfarin (Coumadin) is a medicine that makes the blood take longer to clot; it can prevent stroke in many people with atrial fibrillation. Nevertheless, doctors are sometimes reluctant to prescribe warfarin and patients may be reluctant to take the drug, partly because taking warfarin can lead to bleeding in the gastrointestinal tract or bleeding into the brain.
Why did the researchers do this particular study?
They wanted to find out how often patients with atrial fibrillation use warfarin and what factors were associated with a person using this medicine or not using it.
Who was studied?
The researchers studied 13,428 patients from a large health maintenance organization (HMO) who had atrial fibrillation and no known problem with their heart valves. Nonvalvular atrial fibrillation is the most common type of this heart rhythm problem.
How was the study done?
The researchers used computerized pharmacy and clinical records to find evidence of warfarin use by each patient during the 3 months before and after the diagnosis of atrial fibrillation. They also looked for reasons why the patient should not have gotten prescriptions for warfarin despite having atrial fibrillation (contraindications).
What did the researchers find?
Of the 13,428 patients, 11,082 had no known reason not to get warfarin, but only 55% of them actually got a prescription for it. Warfarin use was lower in patients younger than 55 years old and older than 85 years old and in patients with a previous bleeding problem. Even among patients who had other known risk factors for stroke, such as high blood pressure, and no contraindications to warfarin, less than 60% received warfarin prescriptions. Patients with previous strokes or heart failure were more likely to be given warfarin.
What were the limitations of the study?
This study involved patients from only one HMO, and the findings may not apply to other settings. Pharmacy data tell us only that the patients filled prescriptions for warfarin, but we do not know whether all patients who got the medicine at the pharmacy actually took it. In addition, some patients may have had reasons for not using warfarin that were not listed in the computerized records.
What are the implications of the study?
Many patients who have atrial fibrillation and no known contraindications to the use of warfarin do not receive it. These patients are therefore at unnecessary risk of having a stroke. It will be important to develop strategies to increase the use of warfarin to prevent strokes in people with atrial fibrillation who are good candidates for taking this drug.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  N. Rodondi, E. A. Kerr, and J. V. Selby Poorly Controlled Cardiovascular Risk Factors and ICD-9-CM Codes Ann Intern Med, September 5, 2006; 145(5): 394 - 395. [Full Text] [PDF]
|
|
|
|
|
|
N. Rodondi, T. Peng, A. J. Karter, D. C. Bauer, E. Vittinghoff, S. Tang, D. Pettitt, E. A. Kerr, and J. V. Selby Therapy Modifications in Response to Poorly Controlled Hypertension, Dyslipidemia, and Diabetes Mellitus Ann Intern Med, April 4, 2006; 144(7): 475 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Hylek, J. D'Antonio, C. Evans-Molina, C. Shea, L. E. Henault, and S. Regan Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation Stroke, April 1, 2006; 37(4): 1075 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nieuwlaat, A. Capucci, A. J. Camm, S. B. Olsson, D. Andresen, D. W. Davies, S. Cobbe, G. Breithardt, J.-Y. Le Heuzey, M. H. Prins, et al. Atrial fibrillation management: a prospective survey in ESC Member Countries: The Euro Heart Survey on Atrial Fibrillation Eur. Heart J., November 2, 2005; 26(22): 2422 - 2434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Fang, D. E. Singer, Y. Chang, E. M. Hylek, L. E. Henault, N. G. Jensvold, and A. S. Go Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study Circulation, September 20, 2005; 112(12): 1687 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. McBride A Preliminary Assessment of the Critical Differences Between Novel Oral Anticoagulants Currently in Development J. Clin. Pharmacol., September 1, 2005; 45(9): 1004 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Rothberg, C. Celestin, L. D. Fiore, E. Lawler, and J. R. Cook Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit Ann Intern Med, August 16, 2005; 143(4): 241 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Sherman, S. G. Kim, B. S. Boop, S. D. Corley, J. P. DiMarco, R. G. Hart, L. J. Haywood, K. Hoyte, E. S. Kaufman, M. H. Kim, et al. Occurrence and Characteristics of Stroke Events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) Study Arch Intern Med, May 23, 2005; 165(10): 1185 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Menzin, L. Boulanger, O. Hauch, M. Friedman, C. B. Marple, G. Wygant, J. S Hurley, S. Pezzella, and S. Kaatz Quality of Anticoagulation Control and Costs of Monitoring Warfarin Therapy Among Patients with Atrial Fibrillation in Clinic Settings: A Multi-Site Managed-Care Study Ann. Pharmacother., March 1, 2005; 39(3): 446 - 451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 SPORTIF Executive Steering Committee for the SPORT Ximelagatran vs Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Randomized Trial JAMA, February 9, 2005; 293(6): 690 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Kim and R. Arora Emerging Role of Direct Thrombin Inhibitors in Nonvalvular Atrial Fibrillation: Potential and Peril Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2005; 10(1): 11 - 21. [Abstract] [PDF]
|
|
|
|
|
|
W. E Dager, T. G Vondracek, B. A McIntosh, and E. A Nutescu Ximelagatran: An Oral Direct Thrombin Inhibitor Ann. Pharmacother., November 1, 2004; 38(11): 1881 - 1897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Dager Ximelagatran: A New Antithrombotic Option in Atrial Fibrillation Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2004; 9(3): 151 - 162. [Abstract] [PDF]
|
|
|
|
|
|
M. C. Fang, R. S. Stafford, J. N. Ruskin, and D. E. Singer National Trends in Antiarrhythmic and Antithrombotic Medication Use in Atrial Fibrillation Arch Intern Med, January 12, 2004; 164(1): 55 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Go, E. M. Hylek, Y. Chang, K. A. Phillips, L. E. Henault, A. M. Capra, N. G. Jensvold, J. V. Selby, and D. E. Singer Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation: How Well Do Randomized Trials Translate Into Clinical Practice? JAMA, November 26, 2003; 290(20): 2685 - 2692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Singer A 60-Year-Old Woman With Atrial Fibrillation JAMA, October 22, 2003; 290(16): 2182 - 2189. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Johnston and M. H. Eckman Use of Regression Modeling to Simulate Patient-Specific Decision Analysis for Patients with Nonvalvular Atrial Fibrillation Med Decis Making, September 1, 2003; 23(5): 361 - 368. [Abstract] [PDF]
|
|
|
|
|
|
J. A. Johnston, R. J. Cluxton Jr, P. C. Heaton, J. J. Guo, C. J. Moomaw, and M. H. Eckman Predictors of Warfarin Use Among Ohio Medicaid Patients With New-Onset Nonvalvular Atrial Fibrillation Arch Intern Med, July 28, 2003; 163(14): 1705 - 1710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Savelieva and A. John Camm Atrial fibrillation and heart failure: natural history and pharmacological treatment Europace, January 1, 2003; 5(s1): S5 - S19. [Abstract] [Full Text] [PDF]
|
|
|
Article
